PT  - JOURNAL ARTICLE
AU  - Rebholz, Heike
AU  - Braun, Ralf J.
AU  - Saha, Titas
AU  - Harzer, Oliver
AU  - Schneider, Miriam
AU  - Ladage, Dennis
TI  - Longitudinal monitoring of SARS-CoV-2-specific immune responses
AID  - 10.1101/2021.08.14.21262042
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.14.21262042
4099  - http://medrxiv.org/content/early/2021/08/20/2021.08.14.21262042.short
4100  - http://medrxiv.org/content/early/2021/08/20/2021.08.14.21262042.full
AB  - The Lower Austrian Wachau region was an early COVID-19 hotspot of infection. As previously reported, in June 2020, after the first peak of infections, we determined that 8.5% and 9.0% of the participants in Weißenkirchen and surrounding communities in the Wachau region were positive for SARS-CoV-2-specific immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies, respectively. Here, we present novel data obtained eight months later (February 2021) from Weißenkirchen, after the second peak of infection, with 25.0% (138/552) and 23.6% (130/552) of participants that are positive for IgG and IgA, respectively. In participants with previous IgG/IgA positivity (June 2020), we observed a 24% reduction in IgG levels, whereas the IgA levels remained stable in February 2021. This subgroup was further analyzed for SARS-CoV-2-induced T cell activities. Although 76% (34/45) and 76% (34/45) of IgG positive and IgA positive participants, respectively, showed specific T cell activities, those were not significantly correlated with the levels of IgG or IgA. Thus, the analyses of antibodies cannot surrogate the measurement of T cell activities. For a comprehensive view on SARS-CoV-2-triggered immune responses, the measurement of different classes of antibodies should be complemented with the determination of T cell activities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was financed by internal funds of the Danube Private University, Krems/Donau, Austria.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies involving human participants were reviewed and approved by Kommission fuer wissenschaftliche Integritaet und Ethik (Ethikkommission), Danube Private University, Krems/Donau, Austria.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available from the corresponding authors upon request, considering legal requirements and restrictions.